Corbus Pharmaceuticals Presents Phase 1B Canyon-1 Clinical Trial Data For Crb-913 At Obesityweek® 2026

By Reuters News

- Corbus Pharmaceuticals Holdings, Inc. CRBP.O:

  • CORBUS PHARMACEUTICALS PRESENTS PHASE 1B CANYON-1 CLINICAL TRIAL DATA FOR CRB-913 AT OBESITYWEEK® 2026

  • CORBUS PHARMACEUTICALS HOLDINGS - NO SERIOUS OR SEVERE PSYCHIATRIC ADVERSE EVENTS REPORTED WITH CRB-913

Further company coverage: CRBP.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk